NCT05731323 - D-Cycloserine+iTBS PK Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2022

Primary Completion Date

June 22, 2023

Study Completion Date

June 22, 2023

Conditions

Major Depressive Disorder

Interventions

DRUG

D-cycloserine

Daily oral D-cycloserine dosed 25mg/17.5kg body weight during TMS treatment days (20 days).

DEVICE

Transcranial Magnetic Stimulator

Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.

Trial Locations (1)

T2N 1N4

University of Calgary, Calgary

All Listed Sponsors

lead

University of Calgary

OTHER